Microbiota Interaction with Human and Animal Team (MIHA), Micalis Institute, AgroParisTech, Université Paris-Saclay, INRAE, 78350 Jouy-en-Josas, France.
Department of Clinical Sciences, Nantes-Atlantic College of Veterinary Medicine and Food Sciences (Oniris), University of Nantes, 101 Route de Gachet, 44300 Nantes, France.
Int J Mol Sci. 2021 Jun 4;22(11):6088. doi: 10.3390/ijms22116088.
Inflammatory bowel diseases (IBD) are incurable disorders whose prevalence and global socioeconomic impact are increasing. While the role of host genetics and immunity is well documented, that of gut microbiota dysbiosis is increasingly being studied. However, the molecular basis of the dialogue between the gut microbiota and the host remains poorly understood. Increased activity of serine proteases is demonstrated in IBD patients and may contribute to the onset and the maintenance of the disease. The intestinal proteolytic balance is the result of an equilibrium between the proteases and their corresponding inhibitors. Interestingly, the serine protease inhibitors (serpins) encoded by the host are well reported; in contrast, those from the gut microbiota remain poorly studied. In this review, we provide a concise analysis of the roles of serine protease in IBD physiopathology and we focus on the serpins from the gut microbiota (gut serpinome) and their relevance as a promising therapeutic approach.
炎症性肠病（IBD）是一种无法治愈的疾病，其患病率和全球社会经济影响正在增加。虽然宿主遗传学和免疫的作用已得到充分证明，但肠道微生物失调的作用越来越受到研究。然而，肠道微生物群与宿主之间对话的分子基础仍知之甚少。IBD 患者的丝氨酸蛋白酶活性增加，可能导致疾病的发生和维持。肠道蛋白水解平衡是蛋白酶与其相应抑制剂之间平衡的结果。有趣的是，宿主编码的丝氨酸蛋白酶抑制剂（丝氨酸蛋白酶抑制剂）已有很好的报道；相比之下，肠道微生物群中的丝氨酸蛋白酶抑制剂研究甚少。在这篇综述中，我们对丝氨酸蛋白酶在 IBD 病理生理学中的作用进行了简要分析，并重点介绍了肠道微生物群中的丝氨酸蛋白酶抑制剂（肠道丝氨酸蛋白酶组）及其作为一种有前途的治疗方法的相关性。
